Britain changed the law on cannabis-based medicines in November 2018. It did not build an ordinary NHS route to receive them. Years later, that distinction explains almost everything about the access debate.
Private prescribing has expanded while NHS use remains exceptional. The contrast is not evidence that every private prescription should have been issued by the health service. It is evidence that legality alone did not resolve clinical confidence, commissioning or accountability.
The bottleneck is institutional
Specialist prescribing rules are only one part of the problem. Clinicians must be prepared to take responsibility for a treatment they may not have encountered in training. Commissioners need to know when funding is justified. Services need protocols for monitoring outcomes and adverse effects. For many conditions, national guidance remains cautious.
Each concern is understandable in isolation. Together, they create a system whose safest institutional decision is often to do nothing — even when an individual patient may have exhausted conventional options.
Private care has become the default route
Private clinics can organise specialist assessment, prescribing and follow-up within one service. That integration explains part of their growth. It also transfers the cost of accessing legal treatment to patients, including the recurring cost of consultations and medication.
The result is a policy contradiction: government recognises a class of medicines, but the public system rarely provides a usable pathway to it.
What would move the debate forward
Wider access needs more than pressure to prescribe. It needs clinician education, clear referral criteria, agreed monitoring and a way to turn real-world outcomes into better evidence. It also needs honesty about which conditions have stronger support and where uncertainty remains substantial.
The NHS should not lower clinical standards for cannabis. Nor should it apply a standard so exceptional that lawful prescribing becomes practically impossible. The sensible goal is a route that is cautious, consistent and genuinely available to patients on clinical grounds rather than personal income.
